From Industry Leader to Afterthought? A Surgeon’s Perspective on Covidien (Medtronic Minimally Invasive Therapies Group) Medtronic Decline in Innovation
I’ve been a long-time user and supporter of Covidien (now Medtronic) minimally invasive surgical devices. At one time, this company was synonymous with innovation —setting the gold standard with products like the LigaSure and their surgical stapling platforms. These tools were reliable, intuitive, and forward-thinking. For a while, Covidien drove the future of surgical energy and advanced stapling technology.
But today, it’s hard to ignore the steady erosion of their edge.
A glaring example: the new LigaSure XP. After using it extensively over the past few months, I can confidently say it is a step backward. The ergonomics pale in comparison to the older models while adding nothing to performance. It’s baffling to see a flagship device degrade rather than improve with iteration.
Another example - Medtronic has been teasing a powered circular stapler for years—a product that should have been out long ago if they were keeping pace. It still hasn’t materialized.
And what about Hugo, their long-promised robotic platform? Still elusive. Still unproven. All while Intuitive Surgical continues to release innovative tools that directly address the real-world needs of surgeons—including a new vessel sealer that’s practice-changing. It’s sleek, effective, and honestly a LigaSure-ki-ler.
We’ve reached a point where surgeons are voting with their hands. We’re shifting away from platforms that no longer innovate. Intuitive is delivering what we’ve asked for. Medtronic is… not.
If the current trajectory continues, if Medtronic does not start listening to their users, it’s hard to imagine Hugo becoming a competitive player in the robotic space. And that’s a shame—for a company that once defined surgical innovation, we’re now watching it melt down in real time.
It didn’t have to be this way.